Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26? [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
Management confirmed the annual revenue and earnings outlook it provided in October and issued guidance for the year ahead. In response to Pfizer's latest guidance update, BMO Capital analyst Evan Seigerman reiterated an outperform rating and a $36 per-share price target. If Pfizer stock reaches Seigerman's target, investors who buy at recent prices could see their principal investments gain about 37% in the year ahead. If you're an individual investor, it's important to remember investment-bank analysts have nothing to lose by issuing a bad call -- except their reputations. Below, I'll weigh some of the reasons Pfizer is under pressure against reasons to buy the pharmaceutical giant to see if it's a smart stock to buy now. Why Pfizer's been beaten down Pfizer stock has been beaten down by about 57% from the peak it set back in 2021. It's been under pressure because sales of its COVID-19 vaccine Comirnaty and antiviral treatment Paxlovid have been hard to predict. Combined s
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
- U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal CancerBusiness Wire
- Is Pfizer (PFE) a Cheap NYSE Stock to Invest in Now? [Yahoo! Finance]Yahoo! Finance
- Why Pfizer (PFE) Dipped More Than Broader Market Today [Yahoo! Finance]Yahoo! Finance
- GoComet's Odyssey Singapore 2024 Highlights: When Supply Chain Giants MeetPR Web
PFE
Earnings
- 10/29/24 - Beat
PFE
Sec Filings
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- 12/17/24 - Form 8-K
- PFE's page on the SEC website